1. HBW Insight
  2. >>Health
  3. >>Business
  4. >>Earnings

Genomma Enjoys Strong Q2 Thanks To Big Gains in US

 
• By Tom Gallen

Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation. 

Concept The border between Mexico and America, a magnifying glass over the world map of Mexico
• Source: Shutterstock

Mexico’s Genomma Lab Internacional SAB de CV reported OTC sales up by 32.2% to MXN1.96bn ($86.9m) in the second quarter of 2020 as turnover advanced significantly two of its three reporting regions.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Futura Records First Profits And Targets Eroxon Extension

 
• By Tom Gallen

The US launch of Eroxon ED treatment by Haleon helped Futura Medical record its first ever profit in 2024. The UK firm will now look to capitalize this by seeking US and EU approval for a more potent Eroxon line extension.

‘The Only Certainty Is Uncertainty’ In The UK’s Consumer Health Market

 
• By David Ridley

While uncertainty might reign in the UK consumer health market - which grew by by 8% to £4.1bn ($5.3bn) in 2024 - “opportunity is everywhere” according to NielsenIQ health and beauty insights manager Alex Heffernan.

France’s Boiron Looks To Future After Challenging Year

 
• By Tom Gallen

The homeopathy specialist reported a big decline in profits in 2024 as a move to restructure its ailing French operation hit the bottom line.

Reducing Complexity Helps Weleda Break Sales Record

 
• By Tom Gallen

Swiss firm reports highest revenues in its history as restructure pays off for its pharma and cosmetics businesses in 2024.

More from Business

Pharma Still Nervous While Riding Trump’s Tariff Rollercoaster

 
• By Jessica Merrill

The rollout of Trump’s plan has been a policy whiplash, but despite a 90-day pause on tariffs, the US president still appears to be holding a grudge with industry over drug pricing.

KKR Expands Health & Beauty Portfolio With Deal For Sweden’s Karo

 
• By Tom Gallen

Consumer health player Karo is changing hands from EQT to KKR in a deal thought to value the Stockholm-based firm at over €2.5bn.

‘The Only Certainty Is Uncertainty’ In The UK’s Consumer Health Market

 
• By David Ridley

While uncertainty might reign in the UK consumer health market - which grew by by 8% to £4.1bn ($5.3bn) in 2024 - “opportunity is everywhere” according to NielsenIQ health and beauty insights manager Alex Heffernan.